- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
NovaBay, Galderma enter global agreement to develop Aganocide
Emeryville, Calif. ? NovaBay Pharmaceuticals, which develops anti-infective products for the treatment and prevention of infections without causing resistance, has entered a global agreement with Galderma to develop and commercialize NovaBay's Aganocide, according to a company press release.
Emeryville, Calif.
- NovaBay Pharmaceuticals, which develops anti-infective products for the treatment and prevention of infections without causing resistance, has entered a global agreement with Galderma to develop and commercialize NovaBay’s Aganocide, according to a company press release.
The exclusive agreement is worldwide in scope, with the exception of certain Asian markets, and covers all major dermatological conditions, excluding onychomycosis and orphan drug indications.
NovaBay is expected to receive up to $50 million upon achievement of certain milestones related to acne and impetigo indications, and future royalties on net sales of products, according to the press release.
Galderma will be responsible for the development costs for acne and other indications, with the exception of Japan, and for the development program for impetigo. Galderma is also expected to reimburse NovaBay for use of its personnel due to the collaboration, according to the press release.
